Beam Therapeutics Inc [BEAM] stock is trading at $28.93, up 2.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 3.99% over the last week, with a monthly amount glided 6.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on October 09, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. Previously, BofA Securities upgraded its rating to Buy on March 28, 2025, and kept the price target unchanged to $42. On March 10, 2025, upgrade upgraded it’s rating to Sector Outperform but maintained its price target of $40 on the stock. Cantor Fitzgerald upgraded its rating to an Overweight. Leerink Partners upgraded its rating to an Outperform and raised its price target to $39 on November 06, 2024. In a note dated July 23, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $80 on this stock.
Beam Therapeutics Inc [BEAM] stock has fluctuated between $13.52 and $35.25 over the past year. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $28.93 at the most recent close of the market. An investor can expect a potential return of 19.84% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 55.70M for the trailing twelve months, which represents a drop of -32.03%. Gross Profit Margin for this corporation currently stands at -0.14% with Operating Profit Margin at -10.14%, Pretax Profit Margin comes in at -9.01%, and Net Profit Margin reading is -9.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.43 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.27 points at the first support level, and at 27.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.83, and for the 2nd resistance point, it is at 30.74.
Ratios To Look Out For
For context, Beam Therapeutics Inc’s Current Ratio is 6.02. In addition, the Quick Ratio stands at 6.02 and the Cash Ratio stands at 1.47. Considering the valuation of this stock, the price to sales ratio is 52.71, the price to book ratio is 3.04.
Transactions by insiders
Recent insider trading involved Emany Sravan Kumar, Chief Financial Officer, that happened on Dec 31 ’25 when 6294.0 shares were sold. Chief Legal Officer, Bellon Christine completed a deal on Dec 31 ’25 to sell 1254.0 shares. Meanwhile, FMR LLC sold 459.0 shares on Oct 27 ’25.
